How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative

Simply Wall St.

04/23

Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2629006290"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629006290\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629006290?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-23 14:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629006290","market":"nz","top_or_hot":-1,"title":"How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative","media":"Simply Wall St.","content":"<div>\n<p>Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 14:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","article_id":"2629006290","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629006290","pubTimestamp":1776924878,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding neuroscience veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs.\nThis combination of a board-driven leadership change and a high-profile medical affairs hire could influence how investors assess Helus’ execution capabilities within Cybin’s broader clinical platform.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","BK4007":"制药","HELP":"Cybin Inc"},"translate_title":"Helus Pharma的领导层变动将如何影响Cybin(HELP)的执行叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HELP":1.5,"AIPO":0.62},"content_text":"Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding neuroscience veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs. This combination of a board-driven leadership change and a high-profile medical affairs hire could influence how investors assess Helus’ execution capabilities within Cybin’s broader clinical platform. We’ll now examine how Eric So’s return as Interim CEO at Helus Pharma could affect Cybin’s existing investment narrative and risk profile. Find 61 companies with promising cash flow potential yet trading below their fair value.AdvertisementCybin Investment Narrative RecapTo own Cybin, you need to believe its late stage psychedelic programs can eventually convert scientific data into a viable, clinic based business despite ongoing losses and dilution. The Helus CEO reset and addition of a seasoned medical affairs leader do not change the core near term catalyst, which remains upcoming CYB003 and CYB004 data, but they do sharpen the existing execution risk around running trials and preparing for commercialization under an interim structure. The recent appointment of Dr. Ken Kramer as Senior Vice President of Medical Affairs at Helus stands out in this context. His track record in launching neuroscience treatments aligns directly with Cybin’s clinic focused model and may be particularly relevant as the company presents at the Bloom Burton Healthcare Investor Conference, where investors are watching for updates on how Cybin plans to translate its late stage data into real world adoption and payer discussions. Yet, while leadership changes can look constructive on paper, investors should still be aware of the execution risk if interim governance at Helus were to intersect with... Read the full narrative on Cybin (it's free!)Cybin's narrative projects $174.0 million revenue and $37.4 million earnings by 2029. This implies an earnings increase of about $160.6 million from -$123.2 million today.Uncover how Cybin's forecasts yield a $49.46 fair value, a 757% upside to its current price.Exploring Other PerspectivesHELP 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, projecting only about US$5.0 million of revenue and roughly US$1.0 million of earnings by 2029, and they might see this leadership shake up as reinforcing concerns about clean global trial execution and longer loss making years.Explore 6 other fair value estimates on Cybin - why the stock might be worth just $22.14!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Cybin research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.Ready For A Different Approach?Every day counts. These free picks are already gaining attention. See them before the crowd does:Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Uncover the next big thing with 26 elite penny stocks that balance risk and reward.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}